Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Blood Advances|December 5, 2024
Trial eligibility, treatment patterns, and outcome for venetoclax-based therapy in AML: a prospective cohort studyOfir Wolach, Itai Levi, Boaz Nachmias, et al.
American Journal of Hematology|January 25, 2013
Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter studyDrorit Merkel, Kalman Filanovsky, Anat Gafter-Gvili, et al.
Haematologica|November 21, 2024
Acute myeloid leukemia drug-tolerant persister cells survive chemotherapy by transiently increasing plasma membrane rigidity, that also increases their sensitivity to immune cell killingYael Morgenstern, JongBok Lee, Yoosu Na, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2015
Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndromeYishai Ofran, Kalman Filanovsky, Anat Gafter-Gvili, et al.
Nature Communications|September 14, 2021
The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitorsAli Khateb, Anagha Deshpande, Yongmei Feng, et al.
Blood Cancer Journal|April 21, 2022
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemiaKeith W Pratz, Panayiotis Panayiotidis, Christian Recher, et al.
Leukemia|March 24, 2020
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 studyPau Montesinos, Gail J Roboz, Claude-Eric Bulabois, et al.
The Lancet. Haematology|November 1, 2023
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation studyThomas Pabst, Cristina Papayannidis, Fatih Demirkan, et al.
Blood Neoplasia|March 27, 2026
Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trialJames M Foran, Zhuoxin Sun, Selina M Luger, et al.
Leukemia Research|June 18, 2013
Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic deathJessica K Altman, Alfred Rademaker, Elizabeth Cull, et al.
Pageof 8